Merck cervical cancer shot gives 5-year protection
Key points
- An experimental vaccine from Merck & Co Inc designed to protect women against a virus that causes cervical cancer has proved effective for up to five years, researchers said on Wednesday.
- Women given Gardasil, which Merck is developing with France's Sanofi-Aventis, experienced no cases of cervical and external genital lesions, the precursors of cancer, scientists told a medical meeting in Paris.
- Gardasil is set to compete with GlaxoSmithKline Plc's rival vaccine Cervarix in what industry analysts expect to be a multibillion-dollar market.
- Researchers backed by Glaxo earlier this month reported that women given Cervarix had protection for up to 4-1/2 years.
An experimental vaccine from Merck & Co Inc designed to protect women against a virus that causes cervical cancer has proved effective for up to five years, researchers said on Wednesday.
Women given Gardasil, which Merck is developing with France's Sanofi-Aventis, experienced no cases of cervical and external genital lesions, the precursors of cancer, scientists told a medical meeting in Paris.
Gardasil is set to compete with GlaxoSmithKline Plc's rival vaccine Cervarix in what industry analysts expect to be a multibillion-dollar market.
Researchers backed by Glaxo earlier this month reported that women given Cervarix had protection for up to 4-1/2 years.
Both products protect against the human papillomavirus (HPV), a sexually transmitted infection that causes most cases of cervical cancer, the second-most fatal cancer in women.
Gardasil has already been filed for European and U.S. marketing approval, while Glaxo aims to submit Cervarix in the United States before the end of 2006, after filing in Europe last month.
Glaxo estimates the market opportunity for the new vaccines will be 2 billion pounds ($3.57 billion) to 4 billion pounds ($7.14 billion) a year by 2010.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsStudy finds genomic differences in types of cervical cancer
A new study has revealed marked differences in the genomic terrain of the two most common types of cervical cancer, suggesting that patients might benefit from therapies geared to each type’s molecular idiosyncrasies.…
26 August 2013
NewsPhysicians slow to implement HPV vaccination and cervical cancer screening guidelines
Recent breakthroughs in cervical cancer prevention have resulted in new vaccination and cervical cancer screening guidelines. Recommendations do not always translate into practice, however. Less than one third of…
9 July 2013
NewsSelf-collection of samples for HPV testing shows promise in detection of cervical cancer in Kenya
In Kenya, women face a cervical cancer mortality rate that is approximately 10 times as high as in the United States. A study by researchers at the University of North Carolina at Chapel Hill suggests that training…
